Trial Information

Schizophrenia Study

Novartis is conducting this 12-week, randomized, multi-center, open-label study to assess efficacy, safety and tolerability of two switch approaches in people with schizophrenia that are currently being treated with existing schizophrenia therapies.

To be eligible for this study, you must be:

18-64 years of age (both males and females may participate)
Diagnosed with schizophrenia
Currently taking only one of the following antipsychotics:

risperidone
olanzapine
aripiprazole

Other criteria apply

You are not eligible for the study if you:

Are acutely psychotic and/or exhibit symptoms requiring hospitalization
Have a significant medical condition that may interfere with study participation and/or study assessments; have significant, untreated medical illness; are pregnant or breastfeeding
Have a history or diagnosis suggestive of drug or alcohol dependence in the past 6 months (or if the study's urine drug screen is positive for drugs of abuse)
Have had electroconvulsive therapy (ECT) at any time prior to screening
Other criteria apply

Linda Skaggs
Rush University Medical Center - Treatment Research Center
Treatment Research Center
1700 W. Van Buren Street, 5th Floor
Chicago, IL 60612
Phone: 312-942-6597
Email: linda_m_skaggs@rush.edu

View Map

Research Center Information: Rush University Medical Center - Treatment Research Center

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.